HC Wainwright Issues Positive Estimate for Alumis Earnings

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of Alumis in a research report issued on Monday, March 30th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.70) per share for the quarter, up from their prior estimate of ($0.71). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.82) EPS and FY2026 earnings at ($2.89) EPS.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The company had revenue of $1.93 million during the quarter, compared to analyst estimates of $2.75 million.

Several other research firms also recently issued reports on ALMS. Oppenheimer boosted their price objective on Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Monday. Morgan Stanley lifted their target price on shares of Alumis from $33.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a report on Monday, December 29th. Citigroup restated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. Finally, Raymond James Financial started coverage on shares of Alumis in a research note on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Alumis presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.60.

Alumis Stock Up 2.8%

NASDAQ:ALMS opened at $23.37 on Wednesday. The stock has a fifty day simple moving average of $26.28 and a 200 day simple moving average of $14.91. The firm has a market capitalization of $2.97 billion, a price-to-earnings ratio of -7.64 and a beta of -0.64. Alumis has a 1-year low of $2.76 and a 1-year high of $30.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ieq Capital LLC lifted its position in Alumis by 4.1% in the 4th quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after buying an additional 690 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after acquiring an additional 979 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Alumis by 12.4% in the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after acquiring an additional 1,618 shares during the last quarter. Stoneridge Investment Partners LLC increased its stake in shares of Alumis by 8.1% in the third quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company’s stock worth $118,000 after acquiring an additional 2,210 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after acquiring an additional 2,949 shares in the last quarter.

Insiders Place Their Bets

In other Alumis news, Director James B. Tananbaum acquired 411,764 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the transaction, the director owned 5,702,536 shares of the company’s stock, valued at $96,943,112. The trade was a 7.78% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Foresite Labs, Llc bought 411,764 shares of the stock in a transaction on Thursday, January 8th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the purchase, the insider owned 5,702,536 shares in the company, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 1,823,527 shares of company stock valued at $30,999,959 in the last 90 days. Insiders own 40.70% of the company’s stock.

Key Headlines Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright raised its Q1–Q4 and FY2026 EPS estimates, trimming the FY2026 loss forecast and maintaining a “Buy” rating with a $25 price target — a direct catalyst for investor optimism on ALMS. HC Wainwright raises quarterly and FY2026 EPS estimates
• Positive Sentiment: News reports highlighted an analyst upgrade that pushed trading activity and price higher, reflecting short‑term buying from coverage changes. Alumis (NASDAQ:ALMS) Trading Up 12.1% After Analyst Upgrade
• Positive Sentiment: Chardan Capital gave ALMS a Buy rating, adding another institutional endorsement that can support continued inflows and help sustain the rally. Alumis (NASDAQ:ALMS) Earns Buy Rating from Chardan Capital
• Positive Sentiment: Oppenheimer commentary saying ALMS stock is expected to rise further reinforces the bullish analyst narrative and may attract momentum traders. Alumis (NASDAQ:ALMS) Stock Price Expected to Rise, Oppenheimer Analyst Says
• Neutral Sentiment: HC Wainwright issued a FY2027 earnings forecast (coverage note) — important for modeling but lacking clear upside/downside detail in the briefing; watch for full FY2027 assumptions when released. FY2027 Earnings Forecast for Alumis Issued By HC Wainwright
• Negative Sentiment: An American Banking News headline flagged a “pessimistic forecast” from HC Wainwright in another writeup — a reminder that some coverage still emphasizes downside risk and valuation concerns; mixed messaging increases volatility risk. HC Wainwright Issues Pessimistic Forecast for Alumis (NASDAQ:ALMS) Stock Price

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.